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Abstract While it is clearly recognized that increased
intrarenal nitric oxide (NO) levels elicit natriuresis, confound-
ing data showing that systemic nitric oxide synthase inhibition
(NOSi) also increases sodium excretion (UNaV) poses a co-
nundrum. This response has been attributed to the associated
increases in arterial pressure (AP); however, the increases in
AP and in UNaV are temporally dissociated. The changes in
regional renal haemodynamics induced by NOSi could also
contribute to the alterations of UNaV. To evaluate the roles of
AP and non-AP mechanisms mediating the natriuresis, Nω-
nitro-L-arginine methyl ester hydrochloride (L-NAME) was
infused i.v. at doses ranging from 5 to 50 μg/kg/min in
anaesthetized rats. UNaV, perfusion of the cortex (cortical
blood flow, CBF) and medulla (medullary blood flow, MBF)
with laser-Doppler flowmetry and glomerular filtration rate
(GFR) were measured. UNaV increased from 0.6±0.2 to 1.6±
0.1 μmol/kg/min (P<0.05) with the lower nonpressor doses.
With the higher doses, AP increased from 116±4 to 122±
4 mmHg and UNaV increased from 1.1±0.3 to 3.3±0.7 μmol/
min/g (P<0.002). UNaV increased similarly in a group where
renal AP was maintained at baseline levels. The associated
reductions in CBF (17±5 and 38±5 %) and MBF (27±6 and
52±6%)would be expected to attenuate rather than contribute
to the natriuresis. Plasma atrial natriuretic peptide (ANP)
concentrations increased significantly following NOSi.
Anantin, a natriuretic peptide receptor-A blocker, prevented
or reversed the L-NAME-induced natriuresis without altering
the L-NAME-induced changes in AP or CBF. The results
indicate that increased ANP and related natriuretic peptides
mediate the AP-independent natriuresis, at least partly, elicited
by systemic L-NAME infusion and help resolve the conun-
drum of natriuresis during systemic NOSi.
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Introduction
Endogenously released nitric oxide (NO) plays an important
role in the control of vascular and tubular function in the
kidney [19, 27]. The contribution of endogenous NO to renal
function has been established, in part, from the responses to L-
arginine analogues that inhibit nitric oxide synthase (NOS)
and elicit renal vasoconstriction in dogs and rodents [3, 9, 21,
23, 29, 31]. Furthermore, systemic infusion of NOS inhibitors
is followed not only by a decrease in renal blood flow (RBF)
but also by a prominent increase of mean arterial pressure
(AP), whereas the intra-arterial administration leads mostly to
renal vasoconstriction.
In contrast to the renal vasoconstriction observed consis-
tently, the effects of NOS inhibitors on sodium excretion are
variable and appear to depend on the route of infusion. Sys-
temic infusion has been shown to induce natriuresis and
diuresis [14, 15, 29]; these responses are opposite to the
effects observed following intrarenal administration of NOS
inhibitors where antinatriuresis has been observed [7, 20, 21].
Moreover, renal arterial infusion of an NO donor increases
sodium excretion, demonstrating that the direct effects of NO
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are natriuretic and diuretic [20, 21]. These effects are not
consistently associated with changes in glomerular filtration
rate (GFR), indicating direct effects on tubular transport func-
tion [19]. Studies on epithelial transport have also demonstrat-
ed that NO exerts direct inhibitory effects on sodium transport
in renal tubules [27]. A satisfactory explanation for the
contrasting effects of systemic and direct NOS inhibi-
tion on sodium excretion and urine flow is not apparent,
but the conundrum suggests that an indirect mechanism
activated by the associated cardiovascular responses is
responsible for the natriuresis that occurs during systemic
NOS inhibition.
The increases in sodium excretion following acute system-
ic NOS inhibitor administration have often been attributed to
the associated increases in AP [10, 13, 14, 19]. When a NOS
inhibitor is given systematically, it elicits increases in AP with
simultaneous decreases in renal plasma flow and cortical
blood flow (CBF) but there is a distinct delay in diuresis and
natriuresis [3, 4]. Thus, the natriuresis appears to be tempo-
rally dissociated from the blood pressure response and prob-
ably depends on multiple factors. Shahid et al. [36] reported
that the natriuretic effect of NOS inhibition in mice is medi-
ated, at least in part, by the concomitant generation of TNF-α.
The increases in urine flow and sodium excretion could also
depend on additional mechanisms and factors such as in-
creased release of atrial or brain natriuretic peptide (ANP,
BNP) or CYP-450-dependent arachidonic acid derivatives.
Importantly, Leskinen et al. [17] reported that Nω-nitro-L-
arginine methyl ester hydrochloride (L-NAME) administra-
tion increased plasma levels of immunoreactive ANP, but not
BNP, thus providing a mechanistic link between the cardio-
vascular responses to NOS inhibition and the natriuresis elic-
ited by an augmented ANP secretion.
In the present study, we evaluated the effects of a nonse-
lective NOS inhibitor (L-NAME) on renal sodium and potas-
sium excretion using variable doses including subpressor and
slightly pressor without and with control of renal perfusion
pressure. Independent of AP effects, L-NAME clearly de-
creased RBF. Because the changes in renal cortical and med-
ullary blood flow (MBF) induced by NOS inhibition could
contribute to the altered water and ion excretion [22], we used
laser-Doppler flowmetry to follow separately the changes in
regional blood perfusion in the renal cortex and medulla. In
further experiments, we evaluated the role of ANP or BNP in
mediating the increases in urine flow and sodium excretion by
administering the natriuretic peptide receptor-A (NPR-A)
competitive receptor blocker, anantin [6, 8, 26, 41], during
administration of L-NAME. Finally, wemeasured the changes
in plasma ANP concentration in response to NOS inhibition.
We postulated that the L-NAME-mediated natriuresis is dis-
sociated from the AP responses, still occurs in the absence of
increases in AP and is prevented or attenuated by NPR-A
blockade.
Materials and methods
This protocol was approved by the Institutional Animal Care
and Use Committee of Tulane University Health Sciences
Center. Male Sprague Dawley rats (Bwt 280–340 g),
fed a normal rat diet (TD 90229, Harlan-Teklad) with
free access to water until the day of experiment, were
anaesthetized with Inactin (thiobutabarbital sodium, Sig-
ma, Saint Louis, USA) at 100 mg/kg i.p. and placed on
a heated surgery table to maintain rectal temperature at
37 °C. A polyethylene tube was placed in the trachea, and the
rats were prepared for renal clearance experiments as previ-
ously described [4, 25]. The femoral vein was cannulated for
fluid infusions, and the femoral artery was catheterized
for systemic arterial blood pressure (AP) and heart rate
measurements.
The left kidney was exposed from a subcostal flank inci-
sion and placed in a plastic cup similar to that used for
micropuncture [25]. For timed urine collections, a catheter
was introduced into the ureter and passed to the pelvis. The
renal artery was separated from the renal vein to enable
placement of a noncannulating flow probe, 1 mm in diameter,
connected with a Transonic flowmeter (type T106, Transonic
System Inc., Ithaca, NY, USA) for measurement of the total
RBF. RBF was measured only in experiments where
placement of the probe did not cause technical prob-
lems, but the surgical procedures were performed in
every rat. The blood perfusion rates of the renal cortex
and outer medulla were recorded separately using the
laser-Doppler Periflux 4001 system (Perimed AB,
Jarfalla, Sweden) [4]. The CBF was measured using a
PF 408 probe placed on the kidney surface. The outer
MBF was measured as laser-Doppler flux using a needle
probe (PF 411) inserted into the kidney to a depth of
about 4 mm. After each experiment, the rats were killed with
an overdose of the anaesthetic given i.v. and the position of the
medullary probe was verified by surgically exposing the
location. The laser-Doppler probes were calibrated using
a motility standard (a colloidal suspension of latex par-
ticles). The Brownian motion of the suspension provides
the standard value of 250 perfusion units (1,000 PU=
10 V). Thus, only relative flux values were measured
but the calibration enabled comparison of the results among
animals.
In order to compensate for fluid losses during the surgical
preparation, a 6 % bovine albumin in isotonic saline solution
was infused i.v. at 1.2 ml/h. At the end of surgical preparation
and after placement of laser-Doppler probes, the infusion of
6 % albumin was replaced by one containing 2% albumin and
7.5 % polyfructosan (Inutest, Fresenius Kabi, Linz, Austria)
initiated by a priming dose of 1.6 ml/kg for 5 min and
followed by a continuous infusion at 1.2 ml/h in each rat.
The rats were then allowed to stabilize for 1 h.
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Experimental protocols
Effects of L-NAME on AP, renal haemodynamics and renal
excretion and plasma ANP
After two 30-min control urine collections and measurement
periods, either saline (time control group, n=6) or a nonselec-
tive inhibitor of NO synthase, L-NAME (Sigma, Saint Louis,
USA), was given intravenously. Urine samples were collected
for six consecutive 30-min periods, and a blood sample
was taken in the middle of the first control period and
then repeated every 1 h. In order to evaluate the effects
of the L-NAME dose on the natriuretic responses, L-
NAME was infused at varying doses that ranged from 5
to 50 μg/kg/min. For further analysis, these rats were
divided into two groups: one in which L-NAME did not
affect AP significantly over time and the other in which
AP increased after 30–45 min of infusion. In additional
experiments (n=4), a pressor dose of L-NAME was adminis-
tered but renal perfusion pressure (RPP) was maintained at
control levels using an aortic clamp placed above the left renal
artery.
To check the potential effect of L-NAME on changes in
circulating ANP, blood samples were collected from a sepa-
rate group of rats (n=5) before and after 180 min of infusion
of L-NAME given i.v. at 20 μg/kg/min. The experimental
protocol was similar to that described above with the excep-
tion that regional blood flows (laser-Doppler probes) in the
kidney were not measured.
In another three groups of rats, anantin, a competitive
antagonist of NPR-A, was infused alone (n=4) at 10 μg/kg,
superimposed on L-NAME infusion (n=4) or co-infused with
L-NAME (n=6). This dose of anantin was found to be effec-
tive in the blockade of ANP-dependent diuresis in rats [6].
Anantin was found to inhibit ANP-induced intracellular
cGMP accumulation by competitively binding the ANP re-
ceptor without causing guanylyl cyclase activation [26, 41].
Anantin has no agonist activity and does not inhibit NPR-C
binding or activity [38]. Recently, it was found to abolish the
ANP-dependent decrease in blood pressure induced by
glucagon-like peptide 1 (GLP-1) receptor activation in mice
[24].
After control urine collections and measurement periods
and three consecutive L-NAME infusion (10 μg/kg/min) pe-
riods, 30 min each, needed to induce distinct effects of NOS
inhibitors, anantin was given intravenously for 1 min;
the measurements were continued for the next 180 min.
The effects of anantin alone were studied using a sim-
ilar protocol; however, saline vehicle was infused in-
stead of L-NAME (n=4). In the third group, instead of
a bolus dose, anantin was co-infused (0.6 μg/kg/min) simul-
taneously with L-NAME (10 μg/kg/min) until the end of the
experiment.
Analytical procedures
Anantin (Bachem AG, Bubendorf, Switzerland) was dis-
solved in 50 % acetic acid, aliquoted and stored at −20 °C.
On the day of the experiment, aliquots were diluted to 10μg in
a 300-μl solution of 0.9 % NaCl [6] or added to L-NAME
solution. Urine volumes were determined gravimetrically, and
urine sodium and potassium concentrations were measured by
flame photometry. Polyfructosan concentrations in both urine
and plasma samples were measured by standard spectropho-
tometry. Glomerular filtration rate (GFR) was estimated from
the clearance of polyfructosan.
ANP measurements For the estimation of plasma ANP con-
centrations, blood samples were immediately centrifuged to
separate the plasma. From these plasma samples, an amount of
50 μl from each sample was separated, snap-frozen in liquid
nitrogen and stored at −80 °C until analysed. ANP concentra-
tion in the plasma was measured using an ANP (NPPA) rat
in vitro enzyme-linked immunosorbent assay (ELISA) kit
(Abcam, Cambridge, MA, USA). In this assay, 50 μl of the
plasma samples as well as the ANP standards was put in each
well in the plate to which was added 50 μl of biotinylated
ANP antibody, and incubated for more than 2 h. The colour
absorbance in these incubated samples was determined imme-
diately on a microplate reader at a wavelength of 450 nm. The
concentration of ANP in the unknown samples was deter-
mined from the standard curve generated by the regression
analysis of the values from the samples of known standard
concentrations. In this assay, the minimal detectable dose of
ANP in the samples is ~0.2 ng/ml.
Statistical analysis
The significance of changes within one group over time was
first evaluated by repeated measures analysis of variance
(ANOVA) followed by Student’s t test for dependent
variables. Differences in mean values between groups
were analysed by one-way ANOVA followed by modi-
fied Student’s t test for independent variables. The stan-
dard error of the mean (SEM) was used as the measure of data
dispersion. P<0.05 was taken to indicate significant
difference.
Results
In the time control group, renal function remained steady
and no significant changes were observed in renal
haemodynamics or renal excretion parameters during the
course of the experiments.
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Effects of L-NAME on AP, renal haemodynamics and renal
excretion and plasma ANP
The lower doses of L-NAME (5–20 μg/kg/min) did not
significantly increase AP (Fig. 1a) but decreased blood flow
both in the cortex and medulla by 17±5 % (P<0.02) and 27±
6 % (P<0.01), respectively (Fig. 1b, c). CBF and MBF were
significantly reduced within 30–45 min after the start of drug
administration. The slight increase in urine flow (V) was not
significant; however, sodium excretion (UNaV) increased dur-
ing the 3rd hour of L-NAME infusion, which was mostly due
to the rise in urine sodium concentration 79±11 vs. 230±
30 mmol/l before and after L-NAME, respectively
(Fig. 1d, e). The fractional excretion of sodium increased from
0.65±0.19 to 3.04±1.06 % (P<0.01). Urinary potassium
excretion (UKV) was not affected by L-NAME and was 1.2
±0.3 vs. 1.5±0.2 μmol/min before and after the drug infusion,
respectively. There were no significant changes in GFR
throughout the measurement periods (Fig. 1f).
With the higher dose of L-NAME (50 μg/kg/min), AP
increased significantly by 30 min after the onset of the L-
NAME infusion (from 116±4 to 122±4 mmHg, P<0.001)
and remained elevated throughout the experiment (124±
4 mmHg, P<0.001). RBF changes were similar, but the
decreases in CBF and MBF were greater, averaging 38±5 %
(P<0.01) and 52±6 % (P<0.003), respectively (Fig. 1a–c).
Parallel to the regional blood flows, total RBF also decreased
by 48±0.1 %, from 6.5±0.9 to 3.3±0.4 ml/min/g. The L-
NAME-induced increase of AP was observed before the
increases in urine flow and UNaV. These occurred during
60–90 min after the onset of L-NAME infusion and remained
elevated for the duration of the experiment (Fig. 1d, e). UKV
was similar to that observed with the lower dose and did not
change before and during L-NAME infusion, 1.2±0.2 vs.
1.0±0.1 μmol/min/g. GFR was decreased at the beginning
of the higher dose administration but was not significantly
different from the control in subsequent collection periods
(Fig. 1f).
WhenRPPwas controlled, the effects of the pressor dose of
L-NAME on renal haemodynamics and renal excretion were
similar to that observed when RPP was not controlled. The
decreases in RBF (from 5.3±0.6 to 3.0±0.2 ml/min/g,
P<0.02), CBF and MBF occurred earlier and were followed
distinctly later by the increases in UNaV and urine flow
(Fig. 1). Although systemic AP above the aortic clamp in-

























































































































































L-NAME or saline infusion
Fig. 1 Effects of systemic L-NAME infusion on amean arterial pressure
(AP); b, c renal cortical and medullary blood flow (relative changes),
respectively; d sodium excretion; e urine flow and f glomerular filtration
rate. Black squares represent the nonpresssor lower dose of L-NAME (5–
20 μg/kg/min, n=5), black triangles the pressor higher dose of L-NAME
(50μg/kg/min of L-NAME, n=5) andwhite diamonds the pressor dose of
L-NAME with controlled AP (n=4). White circles indicate the time
control group (n=6). Values are means±SEM. Asterisks indicate signif-
icantly different vs. values before L-NAME at P<0.05 or less
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was maintained within 5 mmHg of the initial pressures
throughout the experiment. As in the other experimental
groups, UKV remained stable throughout the experiment and
was 0.9±0.0 vs. 0.8±0.1 μmol/min/g before and after L-
NAME infusion, respectively. The temporal dissociation be-
tween haemodynamic and natriuretic responses in the exper-
imental groups is shown in Fig. 1. As shown in Fig. 2, a
positive correlation was found between the L-NAME dose
and the relative increases in sodium excretion (r=0.579,
P<0.04, n=14). In contrast, there was not a significant rela-
tionship between the changes in RPP caused by L-NAME and
the relative increases in sodium excretion (r=0.134).
In the additional experimental group in which plasma ANP
concentrations affected by L-NAME infusion were deter-
mined, the plasma ANP concentration increased significantly
(P<0.001) from 0.30±0.09 before vs. 1.07±0.20 ng/ml (n=5)
after the drug administration. This was associated with mod-
erate AP increase, and RBF decrease occurred by 60 min after
the onset of the L-NAME infusion (from 114±4 to 125±
6 mmHg, P<0.01, and 6.1±1.4 to 4.6±1.0 ml/min/g,
P<0.03, respectively). In this group, the RBF decrease (33±
4%)was lower compared to that caused by a higher dose of L-
NAME (−48±0.1 %) but, similar to previous experiments, the
increased AP and decreased RBF occurred earlier than the
increases in V (6.6±08 vs. 10.8±1.9 μl/min/g, P<0.03) and
UNaV (0.5±0.2 vs. 1.4±0.4 μmol/min/g, P<0.05) observed at
the end of the experiment. Also, fractional sodium excretion
increased (0.19±0.09 vs. 0.74±0.16%,P<0.02) despite mod-
est decreases in GFR from 1.56±0.04 to 1.25±0.06 ml/min/g
(P<0.04) parallel AP and RBF changes. Thus, similar to the
results shown in Fig. 1, the haemodynamic and natri-
uretic responses were temporally dissociated in this ex-
perimental group also. UKV did not differ before and during
the drug infusion, 1.4±0.2 vs. 1.2±0.2 μmol/min/g,
respectively.
Effects of treatment with anantin on L-NAME-induced effects
on renal excretion
Anantin, given alone, did not elicit significant changes in CBF
and MBF (193±34 and 160±28 PU, before and after anantin,
respectively) or renal excretion parameters (Fig. 3). In the
group treated with L-NAME, there were increases in AP along
with natriuresis and diuresis. AP was not significantly modi-
fied by anantin bolus (indicated by the arrow in Fig. 3) and
was lower only by 3±3 mmHg (Fig. 3a). Similarly, the de-
crease in RBF as measured by CBF (Fig. 3b) or RBF and
MBF (6.6±0.8, 3.2±0.4 and 3.3±0.5 ml/min/g and 134±16,
105±20 and 95±21 PU, before and after L-NAME and after
L-NAME infusion with anantin, respectively) remained un-
changed. In contrast to the maintained renal haemodynamics,
the urine flow and sodium excretion increases induced by L-
NAMEwere markedly attenuated. The peak in natriuresis was
gradually reduced by 57±3 % (P<0.004) and the peak of
diuresis by 55±3 % (P<0.004) (Fig. 3, right-hand panel).
As in the experimental groups with L-NAME alone, UKV
was not modified throughout the experiment and was 0.8±
0.1, 1.3±0.2 and 0.7±0.2 μmol/min/g before and after L-
NAME and after L-NAME infusion with anantin, respective-
ly. Thus, the natriuretic response induced by L-NAME was
markedly reduced after administration of the NPR-A blocker
despite the maintained elevated AP.
Similar to the effects of bolus injections, the effects on
haemodynamics of continuous infusion of both anantin and
L-NAME (anantin-L-NAME co-infusion) did not modify the
AP increase or CBF decrease (Fig 3a, b) and MBF decrease
121±7 vs. 88±10 PU before and after anantin-L-NAME co-
infusion, respectively. However, during the simultaneous in-
fusion of both drugs, there were no changes in sodium excre-
tion or urine flow (Fig. 3c, d) that occurred when L-NAME
was infused alone (Fig. 1d, e).
Fig. 2 Relationships between L-NAME dose (white squares 5–20 μg/
kg/min, n=5; white triangles 50 μg/kg/min with uncontrolled, n=5; or
white diamonds controlled renal perfusion pressure, RPP, n=4) and
changes in urinary sodium excretion, UNaV (left panel) or L-NAME-
induced changes in RPP (right panel). Xmean value for experiments with
L-NAME dose 50 μg/kg/min, asterisks significantly different vs. before
L-NAME (P<0.05 or less), dagger significant difference between mean
value for dose 50 μg/kg/min with uncontrolled RPP and mean value for
5–20 μg/kg/min of L-NAME (P<0.01). There was not a significant
correlation between the change in RPP and the change in UNaV
(right panel)
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Discussion
Themechanismsmediating the natriuresis in response to acute
systemic infusion of NOS inhibitors have remained uncertain,
but they have often been attributed to the associated increases
in arterial blood pressure [10, 13, 14, 19]. In the first part of the
present study, we infused the NOS inhibitor at doses that
either did not affect AP significantly or produced only mod-
erate increases. Although this experimental set-up eliminated
AP as a confounding factor, it raised the question regarding
the effectiveness of inhibition of NO activity. However, we
clearly observed significant decreases in RBF, CBF andMBF,
indicating that even lower doses of L-NAME are effective in
blocking NOS activity in the kidney vasculature, even when
systemic AP is not affected. The effect on MBF was more
pronounced than on CBF as described previously following
systemic blockade with nitro-L-arginine [4]. From the haemo-
dynamic data, it can be concluded that the doses of L-NAME
were effective in reducing intrarenal NO generation. Further-
more, the clear decrease in MBF demonstrates that the natri-
uresis is independent of MBF because the MBF changes
would predict decreases in sodium excretion [5, 22]. Liang
et al. [18] also showed natriuresis in response to a very low
dose of L-NAME (1 μg/kg/min), without increases in AP or
changes in GFR. They explained the natriuresis by suggesting
increases in NOS in the kidney interstitium as measured by
production of nitrate/nitrite. However, RBF was not measured
which makes it difficult to compare with the results of the
present study. Furthermore, it is unlikely that there would be a
paradoxical effect of L-NAME to increase NO activity in
tubular segments and hence increases in sodium excretion,
even in the face of clear evidence for inhibition of NOS
resulting in renal vasoconstriction and reductions in both
CBF and MBF.
The present results show a positive, significant correlation
between the increases in sodium excretion and the dose of L-
NAME but not with the changes in AP (Fig. 2). This correla-
tion along with the lack of associated changes in GFR indi-
cates that the increase in sodium excretion was the result of an
inhibition of tubular sodium reabsorption by mechanisms
independent of pressure natriuresis. These results pose a co-
nundrum and appear to be at variance with results from
in vitro and micropuncture studies as well as clearance exper-
iments indicating that NO is a potent inhibitor of sodium
transport in renal tubules, and this effect is clearly blocked
by L-NAME [19, 27]. Thus, the natriuresis observed in our
experimental groups suggests that it is not simply the result of
withdrawal of the NO stimulus on tubular transport but rather
from an effect of NOS inhibitors on systemic factors which
then affect tubular sodium reabsorption. The time difference
between the changes in RBF and the changes in sodium
excretion suggests that the natriuretic response has an
extrarenal origin. In considering possible mechanisms, our
attention was drawn to studies indicating that inhibition of
NO activity augmented the release of ANP from isolated rat
atrium [34]. In addition, Leskinen et al. [17] demonstrated an
increase in plasma ANP in response to L-NAME infusion. On
the other hand, inWistar-Kyoto rats (WKY), L-NMMA (other
nonselective NOS inhibitor) caused a marked rise in AP
(30 mmHg), but plasma ANP did not change [13]. Neverthe-
less, contemporary cardiovascular physiology is consistent
with the explanation that the systemic vascular contraction,
in particular of the capacitance vessels, caused by NOS inhib-
























































































Fig. 3 Effects of anantin (Anan, antagonist of natriuretic peptide recep-
tor-A) (black circles) given alone (black squares) co-infused with L-
NAME or (black triangles) superimposed on L-NAME (10 μg/kg/min)
on changes in a mean arterial pressure, b cortical blood flow, c sodium
and d urine excretion. Values are means±SEM.Upward arrows represent
Anan bolus (10 μg/kg) added to L-NAME. Asterisks indicate significant-
ly different from values before L-NAME alone or anantin+L-NAME at
P<0.05 or less
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venous return and right atrial pressure even in the absence of
increases in AP, thus eliciting ANP release [33, 42]. This
explanation is consistent with previous results showing that
systemic NOS inhibition did not elicit natriuresis in chronic
Ang II-infused rats, a condition that already has augmented
vascular constriction [4]. Indeed, we have shown in the cur-
rent study that systemic infusion of a NOS inhibitor at a dose
which exerts moderate effects on AP or renal haemodynamics
led to increases in plasma ANP concentrations which might
then have increased renal sodium excretion by directly
inhibiting tubular sodium reabsorption [19, 27].
The validity of our interpretation was further evaluated by
administration of an ANP receptor blocker superimposed on
the L-NAME-induced natriuresis and diuresis. Importantly,
anantin was found to decrease the augmented urine flow and
sodium excretion and return these values toward control
values even in the absence of changes in either arterial pres-
sure or CBF (Fig. 3). Additional studies demonstrated that co-
infusion of anantin with L-NAME prevented the increase of
sodium excretion even though AP increased and CBF de-
creased. When L-NAME was infused alone, the increase in
sodium excretion was not abolished over the time. Collective-
ly, these data support the conclusion that increased ANP and
perhaps BNP levels in response to systemic L-NAME infu-
sion are responsible, at least in part, for the natriuresis. It has
been demonstrated that an increase in GFR is not a factor
mediating ANP-induced natriuresis, at least when ANP is
given at doses in the physiological range [2]. Presumably,
the effects of activation of NPR-A would be additive to the
effects of increased TNF-α, which has also been reported to
elicit natriuresis during systemic NOS inhibition [36].
Other possible candidates that could be involved in the
natriuretic response appear to be less likely. Indeed,
endothelin (ET-1) in subpressor doses evokes natriuresis [11,
28, 32] despite renal vasoconstriction [11] or decreases in
GFR [29] or without changes in renal haemodynamics [35].
However, it has been shown that NO is a mediator of the
natriuretic effects of collecting duct-derived ET-1 [35, 37].
Accordingly, these results do not support the involvement of
endothelins in mediating L-NAME-induced natriuresis.
NO inhibits renal ω-hydroxylase activity [1, 29, 39], and
withdrawal of NO leads to increased ω-hydroxylase activity
and expression of cytochrome P4A (CYP-4A) [30], the
protein/enzyme responsible for 20-HETE synthesis. Thus, it
is possible that NOS inhibition increases ω-hydroxylase ac-
tivity and 20-HETE and EET synthesis and this would be
expected to inhibit tubular sodium reabsorption and cause
natriuresis. Increased diuresis could depend on enhanced syn-
thesis of diuretic and natriuretic EETs and 20-HETE related to
enhanced heme bioavailability for CYP-450 enzymes, the
consequence of NOS inhibition. The CYP-450-dependent
active agents increase sodium excretion. This influence is best
observed during chronic NOS inhibition, especially in animals
with high Na intake [12, 16, 40]. However, the effects of 20-
HETE and EETs on renal vasculature are opposite to those
observed in our experiments, because NOS inhibition reduced
both CBF and MBF at all the doses used. Renal nerve activity
inhibition as a mediator of natriuretic effects of systemic NO
blockade can also be excluded. It was shown inWKY rats that
renal denervation did not affect GFR and renal excretion
responses to L-NMMA [14].
While acute changes in renal medullary blood flow have
been associated with alterations in sodium and water excre-
tion, a vasoconstrictor infused directly into the renal intersti-
tium leads to selective reduction in MBF accompanied by a
decrease of sodium and water excretion. In addition, infusion
of a vasodilator leads to increases in MBF paralleled by
natriuresis and diuresis. These changes occurred in the ab-
sence of alterations in CBF and AP [22]. These data support
the concept that renal MBF is important in the regulation of
tubular fluid and electrolyte handling; however, the mecha-
nisms that transduce changes in medullary flow into changes
in tubular sodium handling remain to be elucidated [5]. In our
study, the reduction of whole kidney, cortical and MBF fol-
lowing administration of L-NAMEwas observedmuch earlier
than the increases in sodium and water excretion and would
have predicted decreases rather than increases in sodium
excretion. Thus, changes of blood flow probably limited rath-
er than contributed to the sodium excretion following NOS
inhibition. Taken together, the changes in CBF and MBF
probably diminished the inhibition of tubular transport
and hence the magnitude of the natriuresis in response
to L-NAME.
In summary, these data demonstrate that the natriuretic
responses to systemic administration of L-NAME are tempo-
rally dissociated from the changes in AP and occur even under
conditions of controlled arterial blood pressure and thus are
not simply due to increases in arterial pressure. The observa-
tion that natriuresis related to inhibition of NOS was distinctly
later in onset than were the decreases in RBF, in both cortical
andmedullary zones, does not support a functional association
of the two phenomena. In addition, blockade of ANP recep-
tors reversed the natriuresis when given after the L-NAME-
induced natriuresis was at its peak and also prevented the
natriuresis, but not the renal vasoconstriction, when it was
co-infused at the same time as the L-NAME. The evaluation
of the plasma ANP levels which increased significantly fol-
lowing administration of the systemic NOS inhibitor
strengthens our conclusion. Thus, the natriuresis may be due
to systemic effects of NOS inhibition, most likely by stimu-
latingANP, which then exerts direct tubular effects to decrease
sodium reabsorption.
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